Nuo Therapeutics Capital Expenditures (CapEx) Growth & History (AURX)

Nuo Therapeutics's capital expenditures (capex) was $274,756 for fiscal 2025.

View full Nuo Therapeutics company overview

Nuo Therapeutics annual capital expenditures (capex) history

Nuo Therapeutics annual capital expenditures (capex)

Fiscal yearPeriod endedCapital expenditures (CapEx)ChangeGrowth
20252025-12-31$274,756$119,794+77.31%
20242024-12-31$154,962$147,718+2039.18%
20232023-12-31$7,244−$52,748−87.93%
20222022-12-31$59,992$59,992
20212021-12-31$0$0
20202020-12-31$0$0
20192019-12-31$0
20152015-12-31$698,172$215,210+44.56%
20142014-12-31$482,962−$267,735−35.66%
20132013-12-31$750,697
20112011-12-31$66,430−$708,195−91.42%
20102010-12-31$774,625

Nuo Therapeutics capital expenditures (capex) trends

Over the last five fiscal years, Nuo Therapeutics's capital expenditures (capex) increased from $0 to $274,756, a change of $274,756. The latest reported quarter, Q2 2026, shows $253,027.

About the metric

What capital expenditures (CapEx) mean

Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.

Calculation and source

SEC-reported capital expenditures

TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Nuo Therapeutics source filings ↗

Community posts

It’s quiet here.

No posts about AURX yet. Start the conversation.

Write the first post